Literature DB >> 8682647

Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease.

R W Mahley1.   

Abstract

The heparan sulfate proteoglycan (HSPG)/low density lipoprotein (LDL) receptor-related protein (LRP) pathway plays a critical role in apolipoprotein (apo) E-containing lipoprotein metabolism in hepatocytes and other cells, including neurons. In this review, it will be shown that the HSPG sequestration step (i.e., the recruitment and trapping of remnant lipoproteins in the space of Disse in the liver) is an important component of remnant metabolism mediated by apo-E. In vitro studies indicate that the apo-E-containing lipoproteins must first interact with HSPG; only then does the LRP mediate lipoprotein uptake. The differential interaction of apo-EIII and the various mutant forms of apo-E with this pathway before internalization appears to be one factor that modulates the expression of recessive versus dominant type III hyperlipoproteinemia. Furthermore, it is now apparent that the HSPG/LRP pathway is involved in the delivery of apo-E to neurons, where apo-E alters neurite growth and cytoskeletal activity in these cells. Specifically, apo-EIV, which has been associated with the pathogenesis of Alzheimer's disease, inhibits neurite extension and microtubule formation subsequent to the interaction of apo-EIV with the HSPG/LRP pathway.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8682647

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  14 in total

1.  Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate.

Authors:  Jieyun Jiang; Wei Cun; Xianfang Wu; Qing Shi; Hengli Tang; Guangxiang Luo
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 2.  Cellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease.

Authors:  N C Inestrosa; M P Marzolo; A B Bonnefont
Journal:  Mol Neurobiol       Date:  1998       Impact factor: 5.590

3.  Increased expression of apolipoprotein E in transgenic rabbits results in reduced levels of very low density lipoproteins and an accumulation of low density lipoproteins in plasma.

Authors:  J Fan; Z S Ji; Y Huang; H de Silva; D Sanan; R W Mahley; T L Innerarity; J M Taylor
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

4.  Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor.

Authors:  M F Linton; A H Hasty; V R Babaev; S Fazio
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

5.  CD36 and proteoglycan-mediated pathways for (n-3) fatty acid enriched triglyceride-rich particle blood clearance in mouse models in vivo and in peritoneal macrophages in vitro.

Authors:  Narumon Densupsoontorn; Yvon A Carpentier; Radjini Racine; Faith M Murray; Toru Seo; Rajasekhar Ramakrishnan; Richard J Deckelbaum
Journal:  J Nutr       Date:  2008-02       Impact factor: 4.798

6.  Prevalence of the apolipoprotein E Arg145Cys dyslipidemia at-risk polymorphism in African-derived populations.

Authors:  Maen D Abou Ziki; Yael Strulovici-Barel; Neil R Hackett; Juan L Rodriguez-Flores; Jason G Mezey; Jacqueline Salit; Sharon Radisch; Charleen Hollmann; Lotfi Chouchane; Joel Malek; Mahmoud A Zirie; Amin Jayyuosi; Antonio M Gotto; Ronald G Crystal
Journal:  Am J Cardiol       Date:  2013-10-03       Impact factor: 2.778

7.  Glycosaminoglycan-lipoprotein interaction.

Authors:  U Olsson; G Ostergren-Lundén; J Moses
Journal:  Glycoconj J       Date:  2001-10       Impact factor: 2.916

8.  Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.

Authors:  M M Véniant; C H Zlot; R L Walzem; V Pierotti; R Driscoll; D Dichek; J Herz; S G Young
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

9.  Apolipoprotein E and cholesterol in aging and disease in the brain.

Authors:  Elena Posse de Chaves; Vasanthy Narayanaswami
Journal:  Future Lipidol       Date:  2008-10

10.  N-methyl-D-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein.

Authors:  Zhenyu Sheng; Mary Prorok; Brigid E Brown; Francis J Castellino
Journal:  Neuropharmacology       Date:  2008-05-24       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.